Literature DB >> 11109233

A controlled study of imagery rehearsal for chronic nightmares in sexual assault survivors with PTSD: a preliminary report.

B Krakow1, M Hollifield, R Schrader, M Koss, D Tandberg, J Lauriello, L McBride, T D Warner, D Cheng, T Edmond, R Kellner.   

Abstract

Imagery-rehearsal therapy for chronic nightmares was assessed in a randomized, controlled study of sexual assault survivors with posttraumatic stress disorder (PTSD). Nightmares, sleep quality, and PTSD were assessed at baseline for 169 women, who were randomized into two groups: treatment (n = 87) and wait-list control (n = 82). Treatment consisted of two 3-hr sessions and one 1-hr session conducted over 5 weeks. Of 169 participants, 91 women (Treatment, n = 43, Control, n = 48) completed a 3-month follow-up and 78 did not. At follow-up, nightmare frequency and PTSD severity decreased and sleep quality improved in the treatment group with small to minimal changes in the control group. Treatment effects were moderate to high (Cohen's d ranged from 0.57 to 1.26). Notwithstanding the large dropout rate, imagery-rehearsal therapy is an effective treatment for chronic nightmares in sexual assault survivors with PTSD and is associated with improvement in sleep quality and decreases in PTSD severity.

Entities:  

Mesh:

Year:  2000        PMID: 11109233     DOI: 10.1023/A:1007854015481

Source DB:  PubMed          Journal:  J Trauma Stress        ISSN: 0894-9867


  38 in total

1.  Nightmare reduction in a Vietnam veteran using imagery rehearsal therapy.

Authors:  Kate L Berlin; Melanie K Means; Jack D Edinger
Journal:  J Clin Sleep Med       Date:  2010-10-15       Impact factor: 4.062

Review 2.  A systematic review of cognitive-behavioral treatment for nightmares: toward a well-established treatment.

Authors:  Jaap Lancee; Victor I Spoormaker; Barry Krakow; Jan van den Bout
Journal:  J Clin Sleep Med       Date:  2008-10-15       Impact factor: 4.062

3.  Comparative meta-analysis of prazosin and imagery rehearsal therapy for nightmare frequency, sleep quality, and posttraumatic stress.

Authors:  Gilbert Seda; Maria M Sanchez-Ortuno; Carolyn H Welsh; Ann C Halbower; Jack D Edinger
Journal:  J Clin Sleep Med       Date:  2015-01-15       Impact factor: 4.062

4.  Nightmares: Under-Reported, Undetected, and Therefore Untreated.

Authors:  Michael R Nadorff; Danielle K Nadorff; Anne Germain
Journal:  J Clin Sleep Med       Date:  2015-07-15       Impact factor: 4.062

Review 5.  Management of post-traumatic nightmares: a review of pharmacologic and nonpharmacologic treatments since 2010.

Authors:  Monica Escamilla; Mercedes LaVoy; Bret A Moore; Barry Krakow
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

6.  A meta-analysis of imagery rehearsal for post-trauma nightmares: effects on nightmare frequency, sleep quality, and posttraumatic stress.

Authors:  Melynda D Casement; Leslie M Swanson
Journal:  Clin Psychol Rev       Date:  2012-06-30

Review 7.  Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management.

Authors:  Michael J Maher; Simon A Rego; Gregory M Asnis
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 8.  Interactions between disordered sleep, post-traumatic stress disorder, and substance use disorders.

Authors:  Ryan Vandrey; Kimberly A Babson; Evan S Herrmann; Marcel O Bonn-Miller
Journal:  Int Rev Psychiatry       Date:  2014-04

9.  Randomized Controlled Trial of Imagery Rehearsal for Posttraumatic Nightmares in Combat Veterans.

Authors:  Gerlinde C Harb; Joan M Cook; Andrea J Phelps; Philip R Gehrman; David Forbes; Russell Localio; Ilan Harpaz-Rotem; Ruben C Gur; Richard J Ross
Journal:  J Clin Sleep Med       Date:  2019-05-15       Impact factor: 4.062

10.  Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder.

Authors:  Pablo Roitman; Raphael Mechoulam; Rena Cooper-Kazaz; Arieh Shalev
Journal:  Clin Drug Investig       Date:  2014-08       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.